SynthesisBreast cancer research : BCR2025

Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis.

Francisco Cezar Aquino de Moraes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.